Galapagos NV (GLPG)
| Market Cap | 2.21B |
| Revenue (ttm) | 1.31B |
| Net Income (ttm) | 376.76M |
| Shares Out | 65.88M |
| EPS (ttm) | 5.72 |
| PE Ratio | 5.87 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,941 |
| Open | 33.49 |
| Previous Close | 33.49 |
| Day's Range | 33.38 - 33.93 |
| 52-Week Range | 22.59 - 37.78 |
| Beta | 0.10 |
| Analysts | Buy |
| Price Target | 36.50 (+8.44%) |
| Earnings Date | Feb 23, 2026 |
About GLPG
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GLPG stock is "Buy." The 12-month stock price target is $36.5, which is an increase of 8.44% from the latest price.
News
Galapagos FY25: Profits Not Built On Product
Galapagos (GLPG) FY25 results highlight one-time GAAP EPS, shrinking ops, TYK2 focus, and negative EV cash value.
GLPG: RBC Capital Raises Price Target, Reaffirms Sector Perform | GLPG Stock News
GLPG: RBC Capital Raises Price Target, Reaffirms Sector Perform | GLPG Stock News
Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...
Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial Resilience
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Full Year 2025 Galapagos NV Earnings Call Transcript
Full Year 2025 Galapagos NV Earnings Call Transcript
Galapagos GAAP EPS of €4.87, revenue of €1.11B; introduces Q1 and FY26 outlook
Earnings Breakdown: Galapagos Q4
Galapagos (NASDAQ: GLPG) announced its Q4 earnings on Monday, February 23, 2026 at 04:01 PM. Here's a breakdown of the earnings report. Earnings Galapagos beat estimated earnings by 1281.8%, reportin...
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on th...
Galapagos NV (XAMS:GLPG) Q4 2025: Everything You Need to Know Ahead of Earnings
Galapagos NV (XAMS:GLPG) Q4 2025: Everything You Need to Know Ahead of Earnings
Galapagos Q4 2025 Earnings Preview
A Peek at Galapagos's Future Earnings
Galapagos (NASDAQ: GLPG) is set to give its latest quarterly earnings report on Monday, 2026-02-23. Here's what investors need to know before the announcement. Analysts estimate that Galapagos will r...
Galapagos NV: Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLP...
Galapagos Receives Transparency Notification from Bank of America
Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transpa...
Galapagos (GLPG) to Cease Cell Therapy Operations
Galapagos (GLPG) to Cease Cell Therapy Operations
Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities ...
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities ha...
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
Galapagos offers deep value with €3B cash, a focused M&A strategy, and new leadership. Click here to read an analysis of GLPG stock now.
Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study
Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study
Galapagos NV: Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...
GLPG Crosses Above Average Analyst Target
In recent trading, shares of Galapagos NV (Symbol: GLPG) have crossed above the average analyst 12-month target price of $32.50, changing hands for $32.57/share. When a stock reaches the target an ana...
Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy
Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy
Galapagos NV: Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the...
Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transpa...